PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
23-Oct-2024 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement ProQR Therapeutics
23-Oct-2024 LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR DONANEMAB (KISUNLA ®▼) FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE IN ADULT PATIENTS WHO ARE APOLIPOPROTEIN E ε4 HETEROZYGOTES OR NON-CARRIERS Eli Lilly and Company Limited
23-Oct-2024 AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study AMYRA Biotech
23-Oct-2024 Online vs. On-Campus Clinical Research Courses: Which is Right for You? Fusion Technology Solutions
22-Oct-2024 Wobble Genomics Presents Novel Early Detection Technology Demonstrating Exceptional Accuracy in Early-Stage Breast Cancer Wobble Genomics
22-Oct-2024 Innovative Trials in running for industry award in recognizing efforts to improve patient outcomes Innovative Trials
22-Oct-2024 ACI Group offers digital solutions as BCI report highlights widespread supply chain chaos ACI Group
22-Oct-2024 Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024 Vivet Therapeutics
22-Oct-2024 Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024 Ariceum Therapeutics (Ariceum)
22-Oct-2024 Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis AstraZeneca
22-Oct-2024 Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi
18-Oct-2024 Medidata Announces Rave Lite to Support Growth in Early and Late-Stage Clinical Trials Medidata
18-Oct-2024 New first-line treatment of Advanced Bladder (Urothelial) Cancer PADCEVTM (enfortumab vedotin) authorised in combination with KEYTRUDA® (pembrolizumab) Astellas Pharma Inc
18-Oct-2024 Sanofi and Orano join forces to develop next-generation radioligand medicines Sanofi
18-Oct-2024 PUBLICATION DEMONSTRATES POTENTIAL FOR MULTI-MARKER CTC PROFILING IN EARLY PROSTATE CANCER ANGLE plc
18-Oct-2024 Yourgene Health Cystic Fibrosis Base Assay Receives IVDR Accreditation Yourgene Health
18-Oct-2024 SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878 SciRhom GmbH
18-Oct-2024 Sanofi and Orano join forces to develop next-generation radioligand medicines Sanofi and Orano Med
18-Oct-2024 EVERSANA Named a Great Place to Work for Six Consecutive Years; Now Certified Across Nine Countries EVERSANA
18-Oct-2024 New first-line treatment of Advanced Bladder (Urothelial) Cancer PADCEVTM (enfortumab vedotin) authorised in combination with KEYTRUDA® (pembrolizumab) Astellas Pharma Ltd